๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hepatic fibrosis 2006: Report of the third AASLD Single Topic Conference

โœ Scribed by Scott L. Friedman; Don C. Rockey; D. Montgomery Bissell


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
117 KB
Volume
45
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


The third American Associated for the Study of Liver Diseases (AASLD)-sponsored Single Topic Conference on hepatic fibrosis was held in June 2006. The conference was both international, with 6 countries represented, and cross-disciplinary, linking the basic molecular and cellular biology of fibrogenic cells to clinical trial design for emerging antifibrotic therapies. The specific goals of the conference were: (1) to consolidate knowledge about the natural history of fibrosis;

(2) to clarify potential endpoints and markers; (3) to emphasize new antifibrotic targets developed on the basis of advances in basic science; and (4) to understand current critical issues pertaining to clinical trial design. Given the tremendous growth of the field and the constraints of a 2-day format, the selection of speakers was a challenge. A number of topics not included in the oral presentations were featured at poster sessions, lending breadth and depth to the meeting as a whole. Surprising new themes emerged about molecular, clinical, and regulatory aspects of the field, and a consensus emerged that hepatic fibrosis has matured into an integrated discipline that promises to significantly improve the prognosis of patients with fibrosing liver disease.


๐Ÿ“œ SIMILAR VOLUMES


The hepatic circulation in health and di
โœ Vijay Shah; Guillermo Garcรญa-Cardeรฑa; William C. Sessa; Roberto J. Groszmann ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB

Blood flow and vascular resistance in the hepatic vasculature are closely regulated through a balance of vasoactive molecules including nitric oxide (NO), carbon monoxide (CO), endothelin (ET), and prostanoids such as prostacyclin. These vasoregulatory agents interact with unique nonparenchymal cell

Hepatitis C. Development of new drugs an
โœ Jean-Michel Pawlotsky; John G. McHutchison ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 298 KB

hronic hepatitis C virus (HCV) infection affects a large number of patients worldwide. While our current therapies (Table ) are effective in approximately 50% of patients, therapy is costly, prolonged, and associated with significant side effects, and it is not suitable for certain groups of patient

Report on a single-topic conference on โ€œ
โœ John W. Ward; Anna S.F. Lok; David L. Thomas; Hashem B. El-Serag; W. Ray Kim ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 231 KB

and Roche and has received grants from Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Roche, and Merck. David Thomas has been a consultant for Merck and has received grants from Gilead and Merck. Hashem El-Serag has been a consultant for Vertex and has received grants from Bayer and Abbott. Ray Kim